RA Capital Management’s Post

Join me tonight to learn more about these interesting and exciting early stage companies!

Like science founders know all too well that running a lean organization and keeping costs down are vital for hitting milestones and attracting additional capital (especially in today's challenging funding climate). Join us for a three-part series to SPEED UP & DE-RISK your venture: April 4, April 18, May 2 Extend cash runway and maximize potential with a virtual biotech model. Register now and join the conversation! https://lnkd.in/g__qagsV #StartupLife #VirtualBiotech #RegisterToday

🚀 Belgian biotech: a beacon for VCs in uncertain times 🚀 🔬 Amid a global funding dip, with Belgian growth companies raising €770 million in 2023, half of 2022's record, biotech stands strong. VIB spin-offs Aphea.Bio and Dualyx are leading the charge with notable capital increases. Congratulations to their respective teams! 💡 These successes are not just outliers but a testament to VIB's excellence in cultivating top-tier biotech spin-offs. In a landscape marked by economic headwinds, VIB spin-offs are able to navigate heavy seas. 🌟 For venture capitalists seeking resilient and promising investments, VIB's track record is a beacon. Keep an eye out for some of our promising pipeline opportunities in 2024! #biotech #lifesciences #earlystage #venturecapital #innovation #VIB #Belgium #strategicinvestment Source: https://lnkd.in/e-PXcVqs

Once again, we've seen how crucial #networks are for the growth of #earlystage ventures.   We're still thrilled about the success of yesterday's Investors & Portfolio Day, which reflected the past months of our journey very well:    🔖 Our science spinoffs are experiencing outstanding growth trajectories – securing funding even in tough times, among them: Solgate, Prewave, Ribbon Biolabs, G.ST Antivirals, VALANX Biotech, Sarcura , subdron, ReCatalyst, infrared.city, Syntropic, VitreaLab 🔖 We are bringing in top US venture funds in creative ways to foster the growth of our teams and companies on the ground - and tap into US funding and experience at the same time. 🔖Excellent discussion with Christoph Lengauer, Regina Hodits, Darryl B. McConnell and Ingrid Kelly Spillmann on how to get drug discovery firms started. 🔖 The xista ecosystem remains a fertile ground for biotech and deep tech spinoffs, garnering attention from top US-investors.   🔖 The xista team has expanded by 4 members, that’s amazing!   And finally, we’d like to share a #riddle for all VCs among you: ❔Which industry was one of the first to grapple with complex issues related to high-risk capital? Those who attended yesterday's Investors Day got a brief glimpse into the history of venture capital…   #Spinoff #Biotech #DeepTech #Innovation #Investment #Growth #Networking #VentureCapital

"Remember, AI's value lies in delivering better drugs, not just algorithms." -Its amazing to see Dave Latshaw II, PhD, MBA, getting an opportunity to share one of the key reasons we started BioPhy. 👨🔬 Great panel lead by Zach Taft, MBA, Co-Founder, Clinical Research Innovation Consortium (CRIC), Memorial Sloan Kettering Cancer Center 🔬 Accelerating Drug Development: Harnessing AI as a Problem-Solving Tool "Explore the latest in AI/ML investments transforming drug discovery. Case studies showcase AI's role in drug development. From research to clinical, AI enhances efficiency. Cutting-edge advances like LLMs revolutionize drug discovery. Remember, AI's value lies in delivering better drugs, not just algorithms. Prioritize rigorous clinical validation for investor and patient confidence. Join us to invest in a future where AI serves patients and drives real impact."

🌟 Exciting News for the #Biotech Community! 🌟 We are thrilled to spread the word about the upcoming Prague.bio Conference, a premier event designed to connect startups, investors, and biotech professionals across Central Europe. This full-day conference, co-organized by i&i Prague, is a must-attend for anyone in the biotech field. 🗓 Event Date: September 24, 2024 📍 Location: Empire Hall, Slovanský dům, Na Příkopě 22, Prague, Czech Republic Why Attend? ➡ Keynotes: Gain insights from industry leaders like Christian A. Stein of Ascenion GmbH and Petr Jansa, co-founder of Pallando Therapeutics. ➡ Investors Discussion: Hear from top investors including Sebastian Kreuz from Boehringer Ingelheim Venture Fund and Agnes Oertli from LSA Ventures. ➡ IP & Law Experts Panel: Learn from experts like Adrian Bradley from Cleveland Scott York about IP strategy and legal aspects in biotech. ❗ Project registration is open until May 17, 2024. Don’t miss this opportunity to pitch your innovative ideas and connect with potential investors. If there’s strong interest, registration may be extended. https://lnkd.in/d7CKQewB 🤝 Help us spread the word by sharing this post with your colleagues and portfolio companies. #Biotech #Innovation #Startups #Investment #PragueBioConference #Networking #MIHfamily

Endpoints News with the update on current #biotech #funding environment: Privately held drug developers raised about $6.7 billion in the second quarter, marking the best three-month stretch since the beginning of 2022 and the tail end of the high-flying days of the pandemic. That figure — from investment bank William Blair’s latest quarterly analysis — paints a rosy picture for industry fundraising, which has undergone a difficult stretch for several years. But there’s a caveat: Investors are selective. Biotech VC firms are “flocking towards hot stories, Oppenheimer bankers wrote Monday in a quarterly update. “Despite strong private markets activity, deals still took longer to close due to significantly elevated investor selectivity and due diligence rigor. 🔥🔥🔥 Read the article by Kyle LaHucik:

A new VC fund emerges with $310M to create independent, commercial biotechs! 💡 💊 Who?? - Aaron Kantoff - Sam Hall - Tadd Wessel   💊 𝗪𝗵𝗮𝘁??  - Scion Life Sciences on Wednesday made its debut as a venture firm, announcing the close of a $310 million fund to invest in new biotechnology startups. - Led by a trio of biotech veterans with experience at firms like Apple Tree Partners and Medicxi, Scion plans to focus initially on backing a half-dozen life sciences companies. - In addition to offering entrepreneurs funding, Scion plans to manage some research and development capabilities as well as provide operational support. 💊 𝗪𝗵𝘆??   - Scion is pitching a model that shares similarities with an approach startup creators like Flagship Pioneering and Arch Venture Partners have had success with. - The new firm aims to build a small number of "durable" startups equipped with significant resources and funding — a notable emphasis after the past two years saw many young drugmakers struggle to survive.   ❓ 𝑫𝒊𝒅 𝒚𝒐𝒖 𝒌𝒏𝒐𝒘... They don’t plan to build biotechs with the goal of quickly selling them to pharmaceutical buyers. Though M&A is a key piece of the biotech ecosystem, Scion wants its companies to be able to independently commercialise their drugs if they don’t end up partnering with a larger firm. This is going to be an exciting time for biotechs across the globe!! #VC #Investment #pharma #biotech

#fundingalert 💼Company: Vivalyx  💰Funding: €5.4Million ⚡Round: Seed 👥Investors: Consortium, Brightlands Venture Partners, TVF | TechVision Fonds, Arve Capital, Thomas Ebeling, Andrej Henkler, Springboard Health Angels. Vivalyx GmbH, a biotech company was founded in 2022 in Aachen by Andreas Schumacher, Benedict Doorschodt, René H. Tolba, Christian Bleilevens, Malte Brettel, and Marius Rosenberg. The funding enables it to finance the clinical study required for regulatory approval. This crucial step paves the way for the launch of the innovative organ preservation solution, which has the potential to extend the lifespan of donor organs and enhance their vitality. Luc Starmans, Bernhard Kugel, Andrej Henkler Read more - https://lnkd.in/ggpZz5wE To share your startup story write us on - contact@startuprise.co.uk #Vivalyx #biotech #finance #vitality #funding #fundingnews #startupnews #startuprise

This electrifying speech shed light on the world of hard-core technology companies: companies pushing the boundaries of innovation despite facing two key challenges: high initial investment costs for prototypes and significant market and technological risks. However, the speech also highlighted the unique appeal of these companies to investors. It went beyond the typical investor, showcasing a specific type of investment team eager to support bold innovation. The presentation explored key questions: Why do investors favor hard-core technology companies? How can these companies strategically minimize costs in the initial phase while gaining recognition from investors and the market? This is essential information for all hard-core technology founders. The takeaways will empower them to navigate the challenges and unlock the vast potential of their ventures. #hardcoretech #innovation #entrepreneurship #startup #investing #technology #future